2024
Characterizing an Underdiagnosed Condition: Hemophilia in Females
Restrepo V, Prozora S, Louizos E, Van Doren L, Bona R. Characterizing an Underdiagnosed Condition: Hemophilia in Females. Blood 2024, 144: 2584-2584. DOI: 10.1182/blood-2024-210735.Peer-Reviewed Original ResearchPost-partum hemorrhageHeavy menstrual bleedingIron deficiency anemiaLow factor levelsClotting factor levelsHemophilia treatment centersHaemophilia carriersBlood transfusionHemophilia RegistryFactor deficiencyFactor levelsRates of heavy menstrual bleedingFrequency of blood transfusionLife-threatening bleedingFactor replacement therapyManagement of HCAnti-fibrinolytic agentDiagnosis of HCAge of diagnosisHemophilia B carriersYale-New Haven HospitalHealthcare disparitiesNormal factor VIIIHemophilia A carriersFactor activity
2020
Biomarkers of bone disease in persons with haemophilia
Goldscheitter G, Recht M, Sochacki P, Manco‐Johnson M, Taylor J. Biomarkers of bone disease in persons with haemophilia. Haemophilia 2020, 27: 149-155. PMID: 32856388, DOI: 10.1111/hae.13986.Peer-Reviewed Original ResearchConceptsLevels of TNF-aFVIII deficiencyCTX-1Factor VIII (FVIII)-deficient miceBone metabolismIL-10TNF-aHealthy controlsSkeletal healthBone diseaseIncreased risk of fractureMarkers of bone metabolismSevere FVIII deficiencyPlasma samplesLow bone densityCirculating cytokine levelsInterleukin (IL)-12Risk of fractureIL-10 levelsBone-related cytokinesEvaluated plasma samplesRegulate bone metabolismFVIII replacementCytokine levelsFactor deficiency
2019
On‐label compared to off‐label four‐factor prothrombin complex concentrate use: a retrospective, observational study
Cho B, Jung Y, DeMario V, Lau E, Podlasek S, Grant M, Gehrie E, Frank S. On‐label compared to off‐label four‐factor prothrombin complex concentrate use: a retrospective, observational study. Transfusion 2019, 59: 2678-2684. PMID: 31121073, DOI: 10.1111/trf.15355.Peer-Reviewed Original ResearchConceptsUrgent reversalLabel useMortality rateFour-factor prothrombin complex concentrateAcute major bleedingVitamin K antagonistsProthrombin complex concentrate useProthrombin complex concentrateOff-label useCoagulation factor deficienciesHospital mortalityMajor bleedingK antagonistsPatient characteristicsClinical outcomesBlood utilizationExpensive treatment optionsLabel indicationsSingle institutionTreatment optionsComplex concentrateObservational studyFactor deficiencyInvasive proceduresOff label
2014
Macrophage migration inhibitory factor deficiency in chronic obstructive pulmonary disease
Sauler M, Leng L, Trentalange M, Haslip M, Shan P, Piecychna M, Zhang Y, Andrews N, Mannam P, Allore H, Fried T, Bucala R, Lee PJ. Macrophage migration inhibitory factor deficiency in chronic obstructive pulmonary disease. American Journal Of Physiology - Lung Cellular And Molecular Physiology 2014, 306: l487-l496. PMID: 24441872, PMCID: PMC3949087, DOI: 10.1152/ajplung.00284.2013.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAgedAged, 80 and overAnimalsApoptosisCellular SenescenceCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent Kinase Inhibitor p21EmphysemaFemaleHumansIntramolecular OxidoreductasesLungMacrophage Migration-Inhibitory FactorsMaleMiceMice, Inbred C57BLMice, KnockoutMiddle AgedNicotianaPulmonary Disease, Chronic ObstructiveReceptors, ImmunologicSmokeSmokingTumor Suppressor Protein p53Young AdultConceptsChronic obstructive pulmonary diseaseMacrophage migration inhibitory factorPathogenesis of COPDDevelopment of COPDMIF receptor CD74Obstructive pulmonary diseasePulmonary diseaseWT miceReceptor CD74Role of MIFMacrophage migration inhibitory factor deficiencyMigration inhibitory factorNormal alveolar structureMo of ageWild-type controlsMIF concentrationsFormer smokersLung volumePlasma concentrationsSpontaneous emphysemaFactor deficiencyCigarette smokePleiotropic cytokineInhibitory factorAlveolar structures
2011
Continued Transmission of Parvovirus B19 in Plasma-Derived Factor Concentrates After the Implementation of B19 Nucleic Acid Plasma Minipool Screening,
Soucie J, De Staercke C, Chitlur M, Gruppo R, Hooper W, Kessler C, Kulkarni R, Manco-Johnson M, Monahan P, Oakley M, Powell J, Pyle M, Recht M, Riske B, Sabio H, Trimble S. Continued Transmission of Parvovirus B19 in Plasma-Derived Factor Concentrates After the Implementation of B19 Nucleic Acid Plasma Minipool Screening,. Blood 2011, 118: 3378. DOI: 10.1182/blood.v118.21.3378.3378.Peer-Reviewed Original ResearchUniversal Data CollectionNucleic acid testingBleeding disordersB19 transmissionNAT screeningPlasma-derived factor concentratesFactor concentrationsBleeding disorder clinicRare factor deficienciesB19 IgG antibodiesFlu-like illnessParticipants aged 2Clinical characteristics of study participantsLogistic regression analysisAssociated with arthritisHaemophilia inhibitorsB19 antibodiesInhibitor statusB19 DNACharacteristics of study participantsPregnant womenClinical characteristicsParvovirus B19Factor deficiencyProportion of participants
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply